Physician profile
Richard B Smith
NPI 1225107824
$3,245.25
in general payments reported to CMS, 2019-2025
17 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $181 · 2021: $124 · 2022: $535 · 2023: $375 · 2024: $558 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,031.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $730.50 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $542.51 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $509.86 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $476.02 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $218.48 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $169.74 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $155.45 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $139.01 | 2019-2023 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $84.02 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $57.12 | 2024-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $53.75 | 2025 | |
| Braeburn INC. | $23.85 | 2025 | Brixadi |
| Allergan, INC. | $21.90 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.68 | 2024 | Trintellix |
| Axsome Therapeutics, INC. | $16.32 | 2023 | Sunosi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $13.73 | 2023 | Quviviq |
| Sage Therapeutics, LLC | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.